The Safety and Effectiveness of Clarithromycin in the Prevention of Mycobacterium Avium Complex (MAC) Infection in HIV-Infected Patients
Launched by ABBOTT · Aug 30, 2001
Trial Information
Current as of March 27, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- Patients must have:
- • HIV infection.
- • CD4 count \<= 100 cells/mm3.
- • No evidence of MAC.
- • Life expectancy of at least 6 months.
- • Exclusion Criteria
- Concurrent Medication:
- Excluded:
- • Certain restricted drugs (details not available).
- Patients with the following prior conditions are excluded:
- • History of allergy or hypersensitivity to macrolides. Active substance abuse or other conditions that would affect study compliance.
About Abbott
Abbott is a global healthcare company dedicated to improving lives through innovative medical technologies, diagnostics, nutrition, and branded generic pharmaceuticals. With a commitment to advancing health and wellness, Abbott conducts clinical trials to evaluate the safety and efficacy of its diverse portfolio of products, which span multiple therapeutic areas, including cardiovascular, diabetes care, and neurology. The company employs rigorous research methodologies and collaborates with healthcare professionals and institutions worldwide to ensure the highest standards of clinical integrity and patient safety. Abbott's mission is to deliver impactful solutions that enhance patient outcomes and contribute to the advancement of global healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
New York, New York, United States
San Antonio, Texas, United States
Dallas, Texas, United States
Valhalla, New York, United States
Syracuse, New York, United States
Salem, Virginia, United States
Tucson, Arizona, United States
San Francisco, California, United States
San Francisco, California, United States
Tampa, Florida, United States
San Diego, California, United States
Fort Lauderdale, Florida, United States
Charlotte, North Carolina, United States
Memphis, Tennessee, United States
Hollywood, Florida, United States
Fresno, California, United States
San Jose, California, United States
Nashville, Tennessee, United States
Indianapolis, Indiana, United States
Portland, Oregon, United States
Tacoma, Washington, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
Similar Trials